DV Trading LLC Acquires New Shares in Avalo Therapeutics, Inc. $AVTX

DV Trading LLC bought a new stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) during the first quarter, Holdings Channel.com reports. The fund bought 360,064 shares of the company’s stock, valued at approximately $5,376,000. Avalo Therapeutics comprises 0.1% of DV Trading LLC’s investment portfolio, making the stock its 9th biggest position.

Several other institutional investors have also recently made changes to their positions in AVTX. Geode Capital Management LLC boosted its holdings in shares of Avalo Therapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after acquiring an additional 2,648 shares during the period. Glenmede Trust Co. NA grew its position in shares of Avalo Therapeutics by 25.8% in the first quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock valued at $384,000 after purchasing an additional 5,280 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics during the 3rd quarter valued at $143,000. Boothbay Fund Management LLC bought a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at $56,000. Finally, AlphaCentric Advisors LLC purchased a new stake in Avalo Therapeutics during the 1st quarter worth about $174,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on AVTX shares. Weiss Ratings downgraded Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. HC Wainwright decreased their price target on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. Wolfe Research started coverage on shares of Avalo Therapeutics in a report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price target on the stock. Mizuho increased their price target on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Finally, Citizens Jmp cut their price objective on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research report on Thursday, May 14th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.80.

Insider Activity

In other news, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the transaction, the insider owned 3,634 shares of the company’s stock, valued at approximately $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 1,450 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the sale, the insider directly owned 51,776 shares in the company, valued at $931,968. This represents a 2.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 77,513 shares of company stock worth $1,560,121. Insiders own 4.46% of the company’s stock.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $18.25 on Friday. Avalo Therapeutics, Inc. has a fifty-two week low of $6.57 and a fifty-two week high of $24.27. The stock has a market cap of $965.42 million, a P/E ratio of -3.34 and a beta of 0.78. The firm’s fifty day moving average price is $17.02 and its 200-day moving average price is $16.20.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. Sell-side analysts predict that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.